MorphoSys AG
21.7.2021 22:22:12 CEST | ACCESS Newswire | Press release
PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will publish its results for the second quarter and first half 2021 on July 28, 2021 at 10:00pm CEST (4:00pm EDT).
MorphoSys' Management Board will host a conference call and webcast on July 29, 2021 at 2:00pm CEST (8:00am EDT) to present the second quarter and first half financial results 2021 and provide a further outlook for 2021.
The conference call will start with a presentation by the Management Board followed by a Q&A session. Following Board Members will be on the call:
- Jean-Paul Kress, M.D., Chief Executive Officer
- Sung Lee, Chief Financial Officer
- Roland Wandeler, Ph.D., Chief Operating Officer
- Malte Peters, M.D., Chief Research & Development Officer
A live webcast and slides will be made available at the Media and Investors section under Conferences on MorphoSys' website, www.morphosys.com .
Dial-in number for the conference call (2:00pm CEST, 8:00am EDT):
Germany: +49 69 201 744 220
For UK residents: +44 203 009 2470
For US residents: +1 877 423 0830
(all numbers reachable from any geography)
Participant PIN: 72989449#
Please dial in 10 minutes before the beginning of the conference.
A replay of the conference will also be available at the corporate website following the live event.
About MorphoSys
MorphoSys (FSE:MOR)(NASDAQ:MOR) is a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. In 2017, Tremfya (R) (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (R) (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys Group, including the fully owned U.S. subsidiaries MorphoSys US Inc. and Constellation Pharmaceuticals, Inc., has more than 750 employees. For more information visit www.morphosys.com or www.morphosys-us.com .
Monjuvi (R) is a registered trademark of MorphoSys AG.
Tremfya (R) is a registered trademark of Janssen Biotech, Inc.
Forward Looking Statements
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.
For more information, please contact:
Media Contacts:
Thomas Biegi
Vice President
Tel.: +49 (0)89 / 899 27 26 079
thomas.biegi@morphosys.com
Investor Contacts:
Dr. Julia Neugebauer
Senior Director
Tel: +49 (0)89 / 899 27 179
julia.neugebauer@morphosys.com
Jeanette Bressi
Director, US Communications
Tel: +1 617 404 7816
jeanette.bressi@morphosys.com
Myles Clouston
Senior Director
Tel: +1 857 772 0240
myles.clouston@morphosys.com
SOURCE: MorphoSys AG
View source version on accesswire.com:
https://www.accesswire.com/656539/Invitation-to-MorphoSys-Second-Quarter-and-First-Half-2021-Results-Conference-Call-on-July-29-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Winners of this Year's Semmelweis-Richter International Journalism Award Announced21.9.2026 14:05:00 CEST | Press release
BUDAPEST I. KERÜLET, HU / ACCESS Newswire / September 21, 2026 / For the second time, Semmelweis University, with the support of Gedeon Richter, has recognized outstanding health and science journalism from across Europe through the Semmelweis-Richter Journalism Award. Six entries received awards in the "Women's Health" and "Pharmaceutical Strategies and Innovation" categories. The first prizes in the two categories were awarded to an international investigative project on abortion and an article about a technology that uses miniature bioengineered devices to mimic the functions of human organs. The competition received around 60 entries from nearly 20 countries. The Semmelweis-Richter Journalism Award was established to recognize high-quality health and science journalism in Europe. As last year, the competition attracted entries from journalists working for major international media outlets, including The Guardian, the Financial Times, The Times, BBC News, Süddeutsche Zeitung and Púb
NOVELIC Partners with Global DMS Leader Smart Eye to Develop Next-Generation Camera and Radar In-Cabin Monitoring Systems21.9.2026 08:00:00 CEST | Press release
BELGRADE, RS / ACCESS Newswire / September 21, 2026 / NOVELIC, a Belgrade-based innovator in mmWave radar solutions, announced a strategic partnership with Smart Eye, a global leader in Driver Monitoring Systems (DMS) and Interior Sensing AI, to provide OEMs with a well-rounded feature set that satisfies the upcoming Euro NCAP requirements for driver and occupant monitoring. The result is a scalable and cost-effective solution that combines vision and radar for straightforward integration. Since the software is running entirely on the sensor, only a single CAN-Bus interface to the vehicle is required, eliminating the need for external hardware, LVDS interfaces, and added computational load elsewhere in the car. NOVELIC and Smart Eye's innovative system approach will debut at Smart Eye's booth #305 at InCabin Europe 2026 in Barcelona. The demonstration will showcase enhanced performance and compliance with relevant safety protocols through the fusion of radar and vision technologies. NO
Caldwell Strengthens Human Resources Practice with Addition of Ali Palmer as Partner17.9.2026 14:50:00 CEST | Press release
TORONTO, ON AND LONDON, UK / ACCESS Newswire / September 17, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the addition of Ali Palmer as a Partner in the firm's Human Resources Practice. Based in London, Palmer advises boards, chief executive officers and chief people officers on the recruitment of senior human resources leaders, helping organizations build leadership teams that enable growth, transformation and long-term performance. Ali Palmer, Partner in Caldwell's Human Resources Practice. With more than 20 years of executive search and leadership advisory experience, Palmer partners with listed companies, private equity-backed businesses and privately held organizations across a broad range of sectors, with particular expertise in consumer, retail, industrial, financial services, pharmaceutical and technology. She leads executive search assignments across the full human resources function, from chief people officers and chief human resources
Freedom Holding Corp. Backs the FIDE World Championship Match 2026 as General Partner17.9.2026 14:00:00 CEST | Press release
NEW YORK CITY, NY / ACCESS Newswire / September 17, 2026 / Freedom Holding Corp. (NASDAQ:FRHC) is the General Partner of the Salesforce FIDE World Championship Match 2026, the International Chess Federation (FIDE) and Freedom announced today. General Partner is the highest partnership tier of the World Championship. The Match runs from 22 November to 12 December. The Opening Ceremony takes place on 22 November at the Palais des Nations in Geneva. World Champion Gukesh Dommaraju of India defends his title against Javokhir Sindarov of Uzbekistan over 14 classical games. Both players will be twenty at the start of the Match, the youngest title contest since the series began in 1886. Freedom has been a strategic partner of FIDE since 2023. The group is a regular sponsor of the FIDE World Rapid and Blitz Championships and was the title sponsor of the 2024 FIDE World Corporate Chess Championship in New York. Under a 2026 cooperation agreement, Freedom also funds FIDE tournaments, training ce
Bayer to Present How it Rebuilt Global Planning with OMP at Gartner Supply Chain Planning Summit 202617.9.2026 13:52:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / September 17, 2026 / OMP, a leading provider of supply chain planning solutions, invites attendees of the Gartner Supply Chain Planning Summit 2026 in London to its joint session with multinational Bayer. Representatives of the Pharmaceutical division and the global IT department will show what it took to rebuild global planning around faster, higher-quality decisions, how Unison Planning™ supports that at scale, and where AI fits in. Rebuilding planning at Bayer's scale Bayer treated its move to Unison Planning™ as more than a system replacement, rebuilding processes, master data, and ways of working across its global manufacturing and affiliate network. During their Gartner session, Mirja Meyer, Principal Product Manager and Program Lead IT at Bayer, and Karsten Hahm, Program Lead OMP Implementation at Bayer Pharmaceuticals, will cover:What adoption actually tookWhat changed in decision speed and qualityWhere AI fits on the roadmap ahead Sign up for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom